M. Docteur Johan LAW-WAN
✨ Profil synthétique
IA · 06/05/2026Le Dr Johan LAW-WAN est un rhumatologue libéral exerçant à Paris, titulaire d'un DIU en Pathologies osseuses. Ses publications sur PubMed incluent des essais cliniques, indiquant une implication dans la recherche médicale. Il contribue ainsi à l'avancement des connaissances dans son domaine.
Expertises présumées
- Pathologies osseuses
- Essais cliniques
- Rhumatologie
- Ostéoporose
- Ostéonécrose
- Maladies osseuses rares
- Traitements des affections osseuses
Synthèse automatique à partir des sources publiques (HAL, OpenAlex, theses.fr, ClinicalTrials.gov, FAI²R, ANS). Pas une évaluation clinique. Le médecin peut corriger via son compte.
Diplômes
🎓 DES & spécialité ordinale
- DES Rhumatologie
- Rhumatologie (SM)
🏅 DU / DIU
- DIU Pathologies osseuses médicales
🎓 Diplômes
- DE Docteur en médecine
- Diplôme de Podologie
Source : Annuaire Santé ANS (FHIR Practitioner.qualification) · Mises à jour quotidiennes.
🏆 DU / DIU rhumato reconnus
Localisation
Adresses géocodées via la Base Adresse Nationale (api-adresse.data.gouv.fr). Précision indicative.
Lieu de consultation
CABINET DU DR Johan LAW-WAN
CENTRE MEDICAL CHIRURGICAL TOURVILLE — 17 AVENUE DE TOURVILLE, 75007 Paris
Libéral© OpenStreetMap
Tarifs & secteur de conventionnement
Prendre rendez-vous & contact
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Top publications · les plus citées
- 1Predictors of response to TNF inhibitors in rheumatoid arthritis: an individual patient data pooled analysis of randomised controlled trials
RMD open · 2021
Lire l'abstract Crossref ↓
Objective To identify patient characteristics associated with responsiveness to tumour necrosis factor inhibitors (TNFi) in rheumatoid arthritis (RA). Materials and methods Individual patient data from 29 randomised controlled trials (RCTs) evaluating the efficacy of a TNFi versus placebo or conventional therapy were obtained. Response to treatment was assessed in subgroups according to the following baseline characteristics: smoking status, physical activity, sex, age, body mass index, autoantibody profile, disease duration, high initial disease activity defined by Disease Activity Score on 28 joints (DAS28)(C reactive protein (CRP)) >5.1. The primary outcome was the between-treatment group difference in DAS28(CRP) change from baseline to 6 months. The secondary endpoints were the between-treatment group difference in final DAS28(CRP) measured until 6 months and EULAR response criteria until 6 months. Data from each RCT were then pooled by the Mantel-Haenszel method using a random effects model. A linear metaregression was also carried out on two data-sharing platforms separately to support the results. Results Individual data of 11 617 patients from 29 RCTs were analysed. Until 6 months, a significantly higher EULAR non-response rate was observed in obese patients (OR 0.52 vs 0.36 for non-obese, p=0.01). A multivariable regression model performed on 7457 patients indicated that patients treated by TNFi had a final DAS28(CRP) decreased by 0.02 for each year of disease duration (p<0.001), and a 0.21 decreased for patients with a baseline DAS28(CRP) >5.1 (p<0.001). Conclusions In RA, patients who are more responsive to TNFi are those who are non-obese, have a long disease duration and have a high initial disease activity.
Publications scientifiques (2) — classées par pathologie
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Essai clinique1
▼
Essai clinique1
▼- Predictors of response to TNF inhibitors in rheumatoid arthritis: an individual patient data pooled analysis of randomised controlled trials
RMD open · 2021 · Journal Article
Law-Wan J, Sparfel MA, Derolez S, Azzopardi N, et al.
📚 15 cit.🎯 RCR 1.20🔬→🩺 Translationnel
Transversal1
▼
Transversal1
▼- Intramedullary spinal cord metastasis: a rare complication of malignant melanoma
European journal of dermatology : EJD · 2023 · Journal Article
Langbour C, Law-Wan J, Ben-Saad R, Zaragoza J, et al.
